Glenmark said it has collaborated with Pfizer to send off abrocitinib in India utilized for treatment of moderate-to-extreme atopic dermatitis (Promotion). Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and...
QIAGEN has launched two disease test panels for its QIAstat-Dx device in India, including the gastrointestinal panel two and meningitis/encephalitis panel
Fresenius Kabi is posaconazole, an alternative to Noxafil, which treats or prevents severe fungal infections in adults and children at risk of developing fungal infections due to a weakened immune system.
Glenmark Pharmaceuticals Ltd. (Glenmark), a research-focused global pharmaceutical company, and Ichnos Sciences Inc. (Ichnos), an international clinical technology subsidiary, announced the launch of its partnership, Ichnos Glenmark Innovation.
Bajaj Finserv Health, a wholly owned subsidiary of Bajaj Finserv, acquired the entire stake in Vidal Healthcare Services for an enterprise value of Rs 325 crore.
The London Borough of Sutton has confirmed that it has chosen insurer Aviva and developer Socius as partners to progress the development of a world-leading site for cancer research and treatment at the London Cancer Hub (LCH) in Sutton, London
India needs investigator-led clinical trials, especially in oncology. Dr BS Ajaikumar, chairman of HealthCare Global Enterprises, said there should be more opportunities to conduct cross-sectional studies.
Dr Reddy's Research facilities Ltd. (DRL) beat expert assumptions to report a net profit of ₹1,378.9 crore in the second from last quarter finished December (Q3FY24), a 11% year-on-year rise, helped by piece of the pie gains. During that time, the...
Sonablate is pleased to present its most recent innovation At the Rajiv Gandhi Cancer Institute and Research Centre in Delhi. Sonablate HIFU (Extreme focus Centered Ultrasound) innovation. Patients with prostate conditions can now receive precise...
After stabilization with intravenous immunoglobulin therapy, Takeda announced that the European Commission granted approval to Hyqvia (Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase) as maintenance therapy for patients...
, CDSCO.jpg)
